PATIENT SELF-ASSESSMENTS IN ADVANCED PARKINSON'S DISEASE WITHIN UPDRS AND "OFF" TIME SUBGROUPS: COMPARISON OF IPX066 WITH IMEDIATE-RELEASE CARBIDOPA-LEVODOPA

被引：0

作者：

Rubens, R. ^{[1
]}

Rustay, N. R. ^{[1
]}

Khanna, S. ^{[1
]}

Kell, S. ^{[1
]}

Gupta, S. ^{[1
]}

机构：

[1] Impax Labs Inc, Hayward, CA USA

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 03期

关键词：

D O I：

10.1016/j.jval.2015.03.1628

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PND8

引用

页码：A279 / A279

页数：1

共 46 条

[1] Safety of IPX066, an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease
Kestenbaum, Meir
Fahn, Stanley
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 761 - 767
[2] Comparison of IPX066, a Novel Extended-Release Oral Carbidopa-Levodopa Formulation, to Immediate-Release Carbidopa-Levodopa in Patients with Advanced Parkinson's Disease (PD)
Hsu, Ann
Metman, Leonard Verhagen
Ellenbogen, Aaron
O'Connell, Martin
Modi, Nishit B.
Kell, Sherron
Gupta, Suneel
NEUROLOGY, 2010, 74 (09) : A350 - A350
[3] Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson's disease patients: Dosing patterns
Morgan, J.
Stacy, M.
Rubens, R.
Khanna, S.
Gupta, S.
MOVEMENT DISORDERS, 2016, 31 : S659 - S659
[4] Efficacy of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease patients with troublesome dyskinesia
Dhall, R.
Struck, L.
Rubens, R.
Shah, V.
Gupta, S.
MOVEMENT DISORDERS, 2015, 30 : S79 - S80
[5] Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease
Mueller, Thomas
Moehr, Jan-Dominique
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (18) : 2063 - 2071
[6] The influence of baseline disease severity on the efficacy of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease
Espay, A. J.
Liang, G.
Sharma, K.
Rubens, R.
MOVEMENT DISORDERS, 2015, 30 : S81 - S81
[7] The influence of concomitant medication on the efficacy of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease
LeWitt, P.
Metman, L. Verhagen
Rubens, R.
Shah, V.
Kell, S.
Gupta, S.
MOVEMENT DISORDERS, 2015, 30 : S100 - S100
[8] Dosing Patterns During Conversion to IPX066, Extended-Release Carbidopa-Levodopa, from Other Carbidopa-Levodopa Formulations in Advanced Parkinson's Disease Patients
Morgan, John
Stacy, Mark
Rubens, Robert
Khanna, Sarita
Gupta, Suneel
NEUROLOGY, 2016, 86
[9] Onset and duration of clinical effect of IPX066, an extended-release formulation of carbidopa-levodopa, in advanced Parkinson's disease
Ellenbogen, A.
Hauser, R. A.
Modi, N. B.
Hsu, A.
Khanna, S.
Gupta, S.
MOVEMENT DISORDERS, 2015, 30 : S80 - S80
[10] Efficacy and Safety of IPX066, a Carbidopa-Levodopa, Extended-Release Formulation, in Early Parkinson's Disease
Pahwa, Rajesh
Elllenbogen, Aaron
Kell, Sherron
O'Conell, Martin
Hauser, Robert
Fahn, Stanley
Jankovic, Joseph
Pourcher, Emmanuelle
Hsu, Ann
Gupta, Suneel
ANNALS OF NEUROLOGY, 2013, 74 : S47 - S47

← 1 2 3 4 5 →